偶发颅内脑膜瘤的治疗结局:IMPACT队列研究结果
该单中心回顾性队列研究纳入2007至2015年诊断的441例偶发颅内脑膜瘤成人患者,其中44例接受干预。术后需治疗的并发症风险为25%,放疗后28.6%出现限制日常活动的早中期中度不良事件,术后复发率2.5%,放疗后所有脑膜瘤均缩小或影像学稳定。作者认为干预并发症不可忽视,治疗应限于出现症状或影像学显著生长者。
要点
- 441例偶发脑膜瘤中仅44例接受干预,6例初诊即手术,38例主动监测中位24个月后干预。
- 术后需治疗的并发症风险25%,放疗后28.6%出现限制日常活动的早中期中度不良事件。
- 术后复发率2.5%,放疗后所有脑膜瘤均缩小或影像学稳定。
核心结论
- 偶发颅内脑膜瘤治疗后的并发症不可忽视,考虑到多数手术肿瘤为WHO 1级,治疗应保留给出现症状或影像学监测显示显著生长者。
研究设计与样本
- 单中心回顾性队列研究,纳入2007至2015年诊断的偶发颅内脑膜瘤成人患者441例,其中44例接受手术或放疗。
主要发现
- 44例干预患者中位干预年龄56.1岁(四分位距49.6-66.5),女35例、男9例。
- 影像学检查主要适应证为头痛(25.9%),中位脑膜瘤体积4.55 cm³(四分位距1.91-8.61),最常见部位为凸面(47.7%)。
- 6例初诊即手术;38例在中位主动监测24个月(四分位距11.8-42.0)后干预,其中手术34例、放疗4例。
- 治疗指征为影像学进展26例、出现症状6例、患者偏好12例;病理为WHO 1级36例、WHO 2级4例。
- 术后需治疗的外科和内科并发症风险为25%,放疗后28.6%出现限制日常活动的早中期中度不良事件,术后复发率2.5%,放疗后所有脑膜瘤缩小或影像学稳定。
临床怎么用
- 作者认为,偶发颅内脑膜瘤的治疗应保留给出现症状或影像学监测显示显著生长者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Incidental findings such as meningioma are becoming increasingly prevalent. There is no consensus on the optimal management of these patients. The aim of this study was to examine the outcomes of patients diagnosed with an incidental meningioma who were treated with surgery or radiotherapy. METHODS: Single-center retrospective cohort study of adult patients diagnosed with an incidental intracranial meningioma (2007-2015). Outcomes recorded were postintervention morbidity, histopathologic diagnosis, and treatment response. RESULTS: Out of 441 patients, 44 underwent treatment. Median age at intervention was 56.1 years (interquartile range [IQR], 49.6-66.5); patients included 35 women and 9 men. The main indication for imaging was headache (25.9%). Median meningioma volume was 4.55 cm3 (IQR, 1.91-8.61), and the commonest location was convexity (47.7%). Six patients underwent surgery at initial diagnosis. Thirty-eight had intervention (34 with surgery and 4 with radiotherapy) after a median active monitoring duration of 24 months (IQR, 11.8-42.0). Indications for treatment were radiologic progression (n = 26), symptom development (n = 6), and patient preference (n = 12). Pathology revealed World Health Organization (WHO) grade 1 meningioma in 36 patients and WHO grade 2 in 4 patients. The risk of postoperative surgical and medical morbidity requiring treatment was 25%. Early and late moderate adverse events limiting activities of daily living occurred in 28.6% of patients treated with radiotherapy. Recurrence rate after surgery was 2.5%. All meningiomas regressed or remained radiologically stable after radiotherapy. CONCLUSIONS: The morbidity after treatment of incidental intracranial meningioma is not negligible. Considering most operated tumors are WHO grade 1, treatment should be reserved for those manifesting symptoms or demonstrating substantial growth on radiologic surveillance.
引用
- Islim AI, Mohan M, Moon RDC, et al. Treatment Outcomes of Incidental Intracranial Meningiomas: Results from the IMPACT Cohort. World Neurosurg. 2020. PMID: 32200011. doi:10.1016/j.wneu.2020.03.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。